137 related articles for article (PubMed ID: 30260920)
1. CLINICAL COURSE OF PARANEOPLASTIC RETINOPATHY WITH ANTI-TRPM1 AUTOANTIBODY IN JAPANESE COHORT.
Ueno S; Inooka D; Nakanishi A; Okado S; Yasuda S; Kominami T; Sayo A; Morimoto T; Kondo M; Katagiri S; Hayashi T; Terasaki H
Retina; 2019 Dec; 39(12):2410-2418. PubMed ID: 30260920
[TBL] [Abstract][Full Text] [Related]
2. Broad locations of antigenic regions for anti-TRPM1 autoantibodies in paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
Gyoten D; Ueno S; Okado S; Chaya T; Yasuda S; Morimoto T; Kondo M; Kimura K; Hayashi T; Leroy BP; Woo SJ; Mukai R; Joo K; Furukawa T
Exp Eye Res; 2021 Nov; 212():108770. PubMed ID: 34562437
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.
Dalal MD; Morgans CW; Duvoisin RM; Gamboa EA; Jeffrey BG; Garg SJ; Chan CC; Sen HN
Ophthalmology; 2013 Dec; 120(12):2560-2564. PubMed ID: 24053997
[TBL] [Abstract][Full Text] [Related]
4. A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
Kim MS; Hong HK; Ko YJ; Park KH; Ueno S; Okado S; Woo SJ; Joo K
Doc Ophthalmol; 2020 Dec; 141(3):313-318. PubMed ID: 32472235
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.
Morita Y; Kimura K; Fujitsu Y; Enomoto A; Ueno S; Kondo M; Sonoda KH
Jpn J Ophthalmol; 2014 Mar; 58(2):166-71. PubMed ID: 24468869
[TBL] [Abstract][Full Text] [Related]
6. Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction.
Kondo M; Sanuki R; Ueno S; Nishizawa Y; Hashimoto N; Ohguro H; Yamamoto S; Machida S; Terasaki H; Adamus G; Furukawa T
PLoS One; 2011; 6(5):e19911. PubMed ID: 21611200
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.
Hung WC; Cheng HC; Wang AG
Doc Ophthalmol; 2022 Dec; 145(3):263-270. PubMed ID: 36173494
[TBL] [Abstract][Full Text] [Related]
8. Case of paraneoplastic retinopathy with retinal ON-bipolar cell dysfunction and subsequent resolution of ERGs.
Ueno S; Nakanishi A; Nishi K; Suzuki S; Terasaki H
Doc Ophthalmol; 2015 Feb; 130(1):71-6. PubMed ID: 25391361
[TBL] [Abstract][Full Text] [Related]
9. Degeneration of retinal on bipolar cells induced by serum including autoantibody against TRPM1 in mouse model of paraneoplastic retinopathy.
Ueno S; Nishiguchi KM; Tanioka H; Enomoto A; Yamanouchi T; Kondo M; Yasuma TR; Yasuda S; Kuno N; Takahashi M; Terasaki H
PLoS One; 2013; 8(11):e81507. PubMed ID: 24282602
[TBL] [Abstract][Full Text] [Related]
10. Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice.
Xiong WH; Duvoisin RM; Adamus G; Jeffrey BG; Gellman C; Morgans CW
PLoS One; 2013; 8(8):e69506. PubMed ID: 23936334
[TBL] [Abstract][Full Text] [Related]
11. Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy.
Wang Y; Abu-Asab MS; Li W; Aronow ME; Singh AD; Chan CC
BMC Ophthalmol; 2012 Nov; 12():56. PubMed ID: 23148706
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3.
Duvoisin RM; Haley TL; Ren G; Strycharska-Orczyk I; Bonaparte JP; Morgans CW
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2732-2738. PubMed ID: 28549093
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.
Varin J; Reynolds MM; Bouzidi N; Tick S; Wohlschlegel J; Becquart O; Michiels C; Dereure O; Duvoisin RM; Morgans CW; Sahel JA; Samaran Q; Guillot B; Pulido JS; Audo I; Zeitz C
PLoS One; 2020; 15(4):e0231750. PubMed ID: 32324760
[TBL] [Abstract][Full Text] [Related]
14. TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.
Duvoisin RM; Ren G; Haley TL; Taylor MH; Morgans CW
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2330-2335. PubMed ID: 31117125
[TBL] [Abstract][Full Text] [Related]
15. Choroidal atrophy in a patient with paraneoplastic retinopathy and anti-TRPM1 antibody.
Ueno S; Ito Y; Maruko R; Kondo M; Terasaki H
Clin Ophthalmol; 2014; 8():369-73. PubMed ID: 24523577
[TBL] [Abstract][Full Text] [Related]
16. Anti-TRPM1 antibodies in patients with retinal degeneration.
Nishiguchi KM; Fujita K; Inoue T; Nakazawa T
Clin Exp Ophthalmol; 2018 Dec; 46(9):1087-1089. PubMed ID: 29927037
[No Abstract] [Full Text] [Related]
17. Clinical and immunological characterization of paraneoplastic retinopathy.
Makiyama Y; Kikuchi T; Otani A; Oishi A; Guo C; Nakagawa S; Ogino K; Kojima H; Kurimoto M; Yoshimura N
Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5424-31. PubMed ID: 23860756
[TBL] [Abstract][Full Text] [Related]
18. Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss.
Carboni G; Forma G; Bond AD; Adamus G; Iannaccone A
Doc Ophthalmol; 2012 Aug; 125(1):63-70. PubMed ID: 22569848
[TBL] [Abstract][Full Text] [Related]
19. Clinical Findings of Melanoma-Associated Retinopathy with anti-TRPM1 Antibody.
Shinohara Y; Mukai R; Ueno S; Akiyama H
Case Rep Ophthalmol Med; 2021; 2021():6607441. PubMed ID: 34540301
[TBL] [Abstract][Full Text] [Related]
20. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
